What is Oxular?
Oxular is a specialized company dedicated to advancing retinal therapeutics. It leverages proprietary drug formulation and innovative ocular administration technology to develop transformative treatments for a range of retinal diseases. The company's focus on addressing unmet needs in ophthalmology positions it as a key player in the biopharmaceutical landscape.
How much funding has Oxular raised?
Oxular has raised a total of $37M across 1 funding round:
Other Financing Round
$37M
Other Financing Round (2021): $37M with participation from V-Bio Ventures, The IP Group, NeoMed Management, and Forbion
Key Investors in Oxular
V-Bio Ventures
V-Bio Ventures is a life science venture capital fund that co-creates startups and invests in early- to mid-stage companies with high growth potential, focusing on therapeutics. The firm leverages its extensive network and expertise to transform scientific innovations into impactful products.
The IP Group
The IP Group is an intellectual property commercialization company that invests in and helps build science and technology businesses. They focus on identifying and nurturing innovative technologies with strong commercial potential.
NeoMed Management
NeoMed Management is an international venture capital investment firm exclusively focused on the healthcare industry, investing in emerging companies with outstanding growth prospects and innovative medical products.
What's next for Oxular?
With this substantial enterprise-level funding and strategic investment, Oxular is poised for accelerated growth and market expansion. The capital infusion is expected to fuel further research and development, clinical trials, and the scaling of its unique therapeutic technologies. This strategic backing signals strong investor confidence in Oxular's potential to revolutionize the treatment of retinal conditions and capture significant market share.
See full Oxular company page
